Somatostatin-secreting islet cell tumor (somatostatinoma): suppression of growth hormone (GH) release induced by GH-releasing hormone.
A patient with a somatostatin (SRIH)-secreting islet cell tumor, whose only symptoms were dyspepsia and anemia, is described. The diagnosis of somatostatinoma was based on high plasma SRIH concentrations and immunocytochemical findings. The pancreatic exocrine response to secretin was decreased, whereas the insulin and/or glucagon responses to glucose and arginine were normal. Although the basal plasma GH concentration was normal, the plasma GH response to GHRH was subnormal. Gel permeation chromatography studies indicated that SRIH-14 was the predominant form of SRIH in plasma as well as in tumor tissue.
D007516:Adenoma, Islet Cell / Q000378:metabolism*; D000368:Aged; D001120:Arginine; D002850:Chromatography, Gel; D046508:Culture Techniques; D005260:Female; D005947:Glucose; D013006:Growth Hormone / Q000037:antagonists & inhibitors* / Q000097:blood / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone; D006801:Humans; D007150:Immunohistochemistry; D010190:Pancreatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000378:metabolism*; D012633:Secretin; D013004:Somatostatin / Q000097:blood / Q000378:metabolism*; D013005:Somatostatinoma / Q000097:blood / Q000175:diagnosis / Q000378:metabolism*
D012633:Secretin; D013004:Somatostatin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine; D005947:Glucose